News – Page 1131 – Endpoints News

pSivida lines up EMA, FDA applications for eye drug/device as 2nd PhIII delivers positive data

9 years ago

J&J boasts improved cardio safety with SGLT2 franchise drug Invokana

9 years ago

Acceleron scraps dalantercept after it flunks a PhII test for kidney cancer

9 years ago

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

9 years ago

Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory

9 years ago

Seres grabs $20M on PhIII microbiome launch; Gilead submits NDA; Alkermes begins Phase IIIb study

9 years ago

Little Dragonfly bursts onto the I/O scene with a $33M Celgene deal and some of the biggest names in biotech

9 years ago

Coherus craters after Amgen wins reprieve on Neulasta knockoff — FDA rejects marketing application

9 years ago

AstraZeneca punts NASH drug from an ailing Regulus as their lead program goes under for the last time

9 years ago

Seres grabs $20M on PhIII microbiome launch

9 years ago

With an FDA decision looming, Flexion touts new data spotlighting a safety edge for osteoarthritis drug

9 years ago

Merck, Pfizer make their PhIII case for an SGLT2 latecomer to the blockbuster showdown in diabetes

9 years ago

Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA

9 years ago

Trial observers say ‘game over’ for XBiotech's failed PhIII cancer study, the latest in a long line of setbacks

9 years ago

Peer Review: J&J woos Merck’s Mathai Mammen to helm of pharma R&D; Merrimack, Bayer, and Axovant expand leadership ...

9 years ago

8 stars: A look back at ASCO spotlights the top cancer drugs to watch, and 1 to forget

9 years ago

Bristol-Myers shares drop; Regenera offers a lifeline to sinking Alcobra

9 years ago

So what’s star Broad investigator Feng Zhang up to now?

9 years ago

Bristol-Myers vet Douglas Manion bids Big Pharma farewell, takes the helm at Yale spinout Kleo

9 years ago

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

9 years ago

Lexicon 3-for-3 in PhIII for a new diabetes pill, racking up a clean sweep under $1.7B Sanofi pact

9 years ago

Analysts project a big spike in COPD market as new drugs arrive; Valeant raises $930M in latest asset sale

9 years ago

New Chinese VC leads $10M round for a Harvard spinout looking to industrialize platelet manufacturing

9 years ago

Hunting new deals, Eli Lilly buddies up on diabetes R&D with $55M pact

9 years ago

First page Previous page 1128 1129 113011311132 1133 1134 Next page Last page